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Abstract: Autologous fat grafting is a surgical technique in which adipose tissue is transferred
from one area of the body to another, in order to reconstruct or regenerate damaged or injured
tissues. Before reinjection, adipose tissue needs to be purified from blood and cellular debris to avoid
inflammation and preserve the graft viability. To perform this purification, different enzymatic and
mechanical methods can be used. In this study, we characterized in vitro the product of a closed
automatic device based on mechanical disaggregation, named Rigenera®, focusing on two sites of
adipose tissue harvesting. At first, we optimized the Rigenera® operating timing, demonstrating that
60 s of treatment allows a higher cellular yield, in terms of the cell number and growth rate. This result
optimizes the mechanical disaggregation and it can increase the clinical efficiency of the final product.
When comparing the extracted adipose samples from the thigh and abdomen, our results showed
that the thigh provides a higher number of mesenchymal-like cells, with a faster replication rate and
a higher ability to form colonies. We can conclude that by collecting adipose tissue from the thigh
and treating it with the Rigenera® device for 60 s, it is possible to obtain the most efficient product.
Keywords: adipose stem cells; adipose tissue; non-enzymatic method; Rigenera® protocol;
abdomen; thigh
1. Introduction
Whilst adipose tissue has been considered a waste product for years, its essential role as a
regenerative agent has only recently been recognized [1,2]. Indeed, autologous fat grafting has many
applications, including breast reconstruction following tumor therapies [3,4], the treatment of burn
scars and congenital and post-traumatic malformations [5,6], and rejuvenation aims [7]. It is believed
that the main agents responsible for regeneration are adipose-derived stem cells (ASCs), which are adult
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plastic-adherent mesenchymal stem cells abundant in, and easily isolable from, adipose tissue [8–10].
They self-renew and are multi-potent, which means that they have the ability to differentiate, under
appropriate stimulation, into different mesodermal cell lineages, especially into adipocytes, osteocytes,
and chondrocytes [11–16]. After liposuction, the processing of adipose tissue is a key step in avoiding
inflammation and preserving the fat graft viability. The traditional purification method is enzymatic
digestion, which involves the use of collagenase. Briefly, this method consists of collagenase digestion,
centrifugation, and washing steps to remove red blood cells, allowing adipocyte separation from dense
cellular tissue, called the stromal-vascular fraction (SVF) [17]. The SVF contains different kinds of cells,
including ASCs, mesenchymal and endothelial progenitor cells, leukocytes, and pericytes. Although
the enzymatic method is the most effective for SVF isolation, it is an expensive and time-consuming
open system, which requires a further step of enzyme purification. In addition, it destroys the stem-cell
niche, known as the microenvironment, which surrounds the stem cell, allowing interactions with
neighboring cells that promote cell survival, proliferation, and differentiation. Moreover, according to
the Good Manufacturing Practice regulations of the European Parliament and Council (EC regulation
no. 1394/2007), only minimal cell manipulation is allowed in a clinical setting. Therefore, enzymatic
methods are definitely forbidden [18,19]. In clinics, the necessity to purify the adipose tissue in the
operating room immediately after the surgery without laboratory processing and in sterile conditions
is mandatory. For these reasons, many companies have developed automatic closed devices based on
mechanical methods [20–25]. One of these, named Rigenera® (HBW, Turin, Italy), composed of an
engine and disposable sterile capsules, uses mechanical disaggregation operated by steel blades rotating
at 80 rpm, followed by filtration through 70–80 µm pores, to produce immediately injectable micrografts.
The present study aimed to in vitro characterize the product obtained by the Rigenera®
device in terms of the cell viability and morphology, immunophenotyping, colony-formed unit,
and differentiation potential. The study focused on adipose tissue isolated from the thigh and abdomen.
2. Results
The Rigenera® device is a technology which allows the mechanical disaggregation of a small
amount of adipose tissue, in order to obtain an autologous product that is able to promote regeneration.
The procedure consists of tissue manipulation conducted by a ceramic blade and filtration (filter of
80 µm). After processing, the product is collected from the reservoir located at the bottom of the
removable capsule of the Rigenera® device. At first, the composition of the product obtained from
the mechanical disaggregation and harvested from two different anatomical sites—the thigh and
abdomen—was examined at an ultrastructural level. In Figure 1, SEM and TEM images of the product
obtained from adipose tissue of the thigh are shown. No difference was observed at an ultrastructural
level between the two sites of adipose tissue collection (images not shown). The adipose tissue SEM
images (Figure 1a,b) show connective tissue fragments consisting of elastic fibers (see the black arrow in
Figure 1a), collagen fibers (white arrow in Figure 1a,b), and different kinds of isolated cells (Figure 1b).
Among the isolated cells, mesenchymal-like cells (Figure 1c), characterized by rough endoplasmic
reticulum (see the black arrow in Figure 1c) and small size lipidic droplets (white arrow, Figure 1c)
were visualized by TEM.
In order to determine how the mechanical processing time (seconds of sample treatment with
ceramic blades) affects the cellular yield of the device, the number of ASCs, the growth rate, and the
cell morphology were evaluated. Based on preliminary results [18], the best processing time was
chosen among 30, 45, and 60 s. At first, the cells were counted at passage 0 (Figure 3A). The number of
cells with 60 s treatment was much higher compared to 45 s and 30 s (respectively, 15.16 × 106 ± 0.49
compared to 6.84 × 106 ± 0.19 and 4.13 × 106 ± 0.33 for the abdomen and 21 × 106 ± 0.16 compared to
9 × 106 ± 0.35 and 7.2 × 106 ± 0.28 for the thigh, as shown in Figure 3a). After one week, only cells
capable of forming fibroblast-like colonies attached to the flask and were countable. Compared to the
60 s treatment, the thigh cell yield after the 45 s treatment was about 42% and after 30 s, it was about
20% (see the tab in Figure 3). In addition, the mean time of confluence was 8 ± 2.8 days lower with 60 s
Int. J. Mol. Sci. 2020, 21, 3081 3 of 16
treatment than with 45 s treatment. The 30 s-treated cells grew very slowly and were discarded after 45
days (Figure 3b). In the case of abdominal cell extraction, the cell yield of the 60 s treatment was about
36% compared to the 45 s treatment, whereas the 30 s-treated cell yield was about 5%. The mean time
of confluence was 7 days less with 60 s treatment than with 45 s treatment (Figure 3c). Additionally, for
abdomen samples, the 30 s treatment cells grew very slowly and were discarded after 45 days (see
the tab in Figure 3). By calculating the mean cell growth per day, 60 s treatments showed a higher
replication rate (29.23 × 103 and 7.27 × 103 for the thigh and abdomen, respectively), as reported in the
table of Figure 3. The ASC micrographs in Figure 3 (Figure 3d–k) clearly represent the cell morphology
in the flask. The Rigenera® treatment did not affect the cell morphology compared to cells obtained
from enzymatic digestion (g–k), exhibiting a homogeneous fibroblast-like morphology. Indeed, no
signal of suffering was observed and the membranes and nuclei were well-preserved (Figure 3d–f,h–j
for the thigh and abdomen, respectively). By analyzing the results obtained for the cell yield, number of
cells, and growth rate, the 60 s treatment can be considered the most efficient for the Rigenera® method.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 3 of 17 
 
  
Figure 1. Representative SEM (a) and (b) and TEM (c) images of the Rigenera® product obtained from 
the thigh. The Rigenera® device provides fragments consisting of elastic fibers ((a) black arrow), 
collagen fibers ((a) and (b) white arrow), and different kinds of isolated cells (b), including 
mesenchymal-like cells (c), characterized by rough endoplasmic reticulum (black arrow) and lipidic 
droplets (white arrow). No differences at an ultrastructural level were found between the two sites of 
adipose tissue collection (thigh and abdomen). 
In order to determine how the mechanical processing time (seconds of sample treatment with 
ceramic blades) affects the cellular yield of the device, the number of ASCs, the growth rate, and the 
cell morphology were evaluated. Based on preliminary results [18], the best processing time was 
chosen among 30, 45, and 60 s. At first, the cells were counted at passage 0 (Figure 2A). The number 
of cells with 60 s treatment was much higher compared to 45 s and 30 s (respectively, 15.16 × 106 ± 
0.49 compared to 6.84 × 106 ± 0.19 and 4.13 × 106 ± 0.33 for the abdomen and 21 × 106 ± 0.16 compared 
to 9 × 106 ± 0.35 and 7.2 × 106 ± 0.28 for the thigh, as shown in Figure 2a). After one week, only cells 
capable of forming fibroblast-like colonies attached to the flask and were countable. Compared to the 
60 s treatment, the thigh cell yield after the 45 s treatment was about 42% and after 30 s, it was about 
20% (see the tab in Figure 2). In addition, the mean time of confluence was 8 ± 2.8 days lower with 60 
s treatment than with 45 s treatment. The 30 s-treated cells grew very slowly and were discarded after 
45 days (Figure 2b). In the case of abdominal cell extraction, the cell yield of the 60 s treatment was 
about 36% compared to the 45 s treatment, whereas the 30 s-treated cell yield was about 5%. The 
mean time of confluence was 7 days less with 60 s treatment than with 45 s treatment (Figure 2c). 
Additionally, for abdomen samples, the 30 s treatment cells grew very slowly and were discarded 
after 45 days (see the tab in Figure 2). By calculating the mean cell growth per day, 60 s treatments 
showed a higher replication rate (29.23 × 103 and 7.27 × 103 for the thigh and abdomen, respectively), 
as reported in the table of Figure 2. The ASC micrographs in Figure 2 (Figure 2d–k) clearly represent 
the cell morphology in the flask. The Rigenera® treatment did not affect the cell morphology 
compared to cells obtained from enzymatic digestion (g–k), exhibiting a homogeneous fibroblast-like 
morphology. Indeed, no signal of suffering was observed and the membranes and nuclei were well-
preserved (Figure 2d–f and h–j for the thigh and abdomen, respectively). By analyzing the results 
obtained for the cell yield, number of cells, and growth rate, the 60 s treatment can be considered the 
most efficient for the Rigenera® method. 
Figure 1. Representative SEM (a,b) and TEM (c) images of the Rigenera® product obtained from the
thigh. The Rigenera® device provides fragments consisting of elastic fibers ((a) black arrow), collagen
fibers ((a,b) white arrow), and different kinds of isolated cells (b), including mesenchymal-like cells
(c), characterized by rough endoplasmic reticulum (black arrow) and lipidic droplets (white arrow).
No differences at an ultrastructural level were found between the two sites of adipose tissue collection
(thigh and abdomen).
Next, the cells obtained from 60 s treatment were compared with those obtained with the enzymatic
method. After one week of culture, the Rigenera® cell yield for the thigh was 62% and for the abdomen,
was around 25%, compared to the enzymatic method (see the tab in Figure 2).
Additionally, the replication rate was lower when using the Rigenera® device: extracted cells
reached the confluence in 21 ± 1.4 and 27 ± 3.7 days with Rigenera® (for the thigh and abdomen,
respectively), while, when using the enzymatic method, they took 13 ± 3.5 and 12 ± 2.30 days (for the
thigh and abdo en, respectively), as reported in the tab of Figure 4.
Compari g the two sites of extraction, the cell yi ld for the abdomen w s about 31% lower than
that of th igh. Moreov r, the cells extracted from the thigh reach d confluence 6 ± 2.3 days before
the c lls extracted from the abdomen (see the ab in Figure 4), demonstrating a higher replicative ate.
The histograms in Figure 2a,b show the number of cells from cellu ar passages 2 (p2), 6 (p6), and
10 (p10). Although the resulting rate of replication was higher with the enzymatic method, and the cells
obtained with the enzymatic method were able to reach confluence faster than cells obtained with the
Rigenera® method, at high passages (i.e., 10), no statistically significant difference in cell number was
observed between the Rigenera®-obtained cells and Collagenase digestion (Figure 2a,b, p-value < 0.05).
This means that, at these passages, the growth rate was comparable. Figure 2c compares the replication
rate (in terms of the number of cells at passage 2–6 and 10) of the thigh and abdomen. The difference
is clear at the low cellular passage (3.02 × 105 cells for the thigh and 9.92 × 104 cells of the abdomen
at passage 2), while the difference between the thigh and abdomen was not statistically significant
after a long period of culture and many passages (such as at p10) (p-value < 0.05) (Figure 2c). Finally,
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the morphological analysis highlighted a slight difference between the thigh and abdomen: for example,
the cells obtained from the abdomen were flatter and more widely spread (see Figure 2d).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 17 
 
  
Figure 3. Comparison of Rigenera® and the enzymatic method. (a) Growth rate comparison of ASCs 
from Rigenera® extracted from the thigh and the enzymatic method. (b) Growth rate comparison of 
ASCs from Rigenera® extracted from the abdomen and the enzymatic method. (c) Growth rate 
comparison of ASCs extracted with Rigenera® from the thigh and abdomen. (d) Microscopic images 
(resolution 10×) of ASCs at high passages (p10). The tab shows all of the results obtained. 
Additionally, the replication rate was lower when using the Rigenera® device: extracted cells 
reached the confluence in 21 ± 1.4 and 27 ± 3.7 days with Rigenera® (for the thigh and abdomen, 
respectively), while, when using the enzymatic method, they took 13 ± 3.5 and 12 ± 2.30 days (for the 
thigh and abdomen, respectively), as reported in the tab of Figure 4. 
Figure 2. Comparison of Rigenera® and the enzymatic method. (a) Growth rate comparison of ASCs
from Rigenera® extracted from the thigh and the enzymatic method. (b) Growth rate comparison
of ASCs from Rigenera® extracted from the abdomen and the enzymatic method. (c) Growth rate
comparison of ASCs extracted with Rigenera® from the thigh and abdomen. (d) Microscopic images
(resolution 10×) of ASCs at high passages (p10). The tab shows all of the results obtained.
In order to compa the ability to form colonies of ASCs obtained from the thigh and abdomen,
colony-forming unit-fibroblast (CFU-F) assays were performed. Figure 4 displays representative
micrographs of CFU-F detected by Toluidine Blue staining after 15 days of Rigenera® treatment
(Fi ure 4a, thigh, and b, abdomen) compared with enzymatic digestion (Figure 4d, thigh, and b,
abdomen). The images show that both ASCs treated with Rigenera® and isolated from the thigh
and abdomen were able to grow forming clusters, but larger colonies (formed by a higher number of
cells) could be observed in samples obtained from the thigh compared to those from the abdomen
(Figure 4a,b). These differences are not evident in the samples treated with enzymatic digestion
(Figure 4d,e). Moreover, when the CFU-F numbers were counted, more colonies were detected in
samples isolated from the thigh (16.17 ± 1.8) compared to the abdomen (8.83 ± 1.1), as reported in
Figure 4c. No statistical differences in the number of CFU-F between thigh and abdomen samples
treated with enzymatic digestion were found.
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Figure 2. Rigenera® method optimization. The tabs show all of the results obtained. (a) Cell viability 
test with the trypan blue exclusion method. At passage 0, the number of total cells was much higher 
with the 60 s Rigenera® treatment compared to the other timings (30 and 45 s). After one week, the 
number of pure adipose-derived stem cells (ASCs) was still higher with the 60 s Rigenera® treatment 
in both the thigh (b) and abdomen (c). Microscopic images (resolution 10×) of cells extracted from the 
thigh (d–f) and abdomen (h–k) with the Rigenera® device operating at different timings of 30 s (d,h), 
45 s (e,i), and 60 s (f,j), and the enzymatic method (g,k). 
Next, the cells obtained from 60 s treatment were compared with those obtained with the 
enzymatic method. After one week of culture, the Rigenera® cell yield for the thigh was 62% and for 
the abdomen, was around 25%, compared to the enzymatic method (see the tab in Figure 3).  
Fig re 3. Rigenera method optimization. The tabs show all of the results obtained. (a) Ce l viability
test ith t e try an l e excl sio et . At passage 0, the nu ber of total ce ls as uch higher
it t treatment compared to the other ti ings (30 and 45 s). fter one eek, t e
nu ber of r i - i ll ill i i i treat ent
in both the thig ( ) a a e (c). icroscopic i a es (r s l ti ) of cells extracted fro the
thigh ( –f) a ab o e ( – ) it t e i e er device operating at different timings of 30 s (d,h),
45 s (e,i), a 60 s (f,j), t tic t ( , ).
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Figure 4. The colony-forming unit-fibroblast (CFU-F) assay of ASCs obtained by Rigenera® ((a) thigh 
and (b) abdomen) and the enzymatic method ((d) thigh and (e) abdomen). CFU-F values were 
determined at day 15 after plating using the Toluidine Blue staining method. ASCs extracted from the 
thigh (a–d) formed larger colonies containing more cells than those extracted from the abdomen (b–e); 
(c) CFU-F numbers at day 15 obtained by the Rigenera® device; CFU-F numbers showed significant 
differences between the two groups (thigh and abdomen). (d) CFU-F numbers at day 15 obtained by the 
enzymatic method; CFU-F numbers showed no significant differences between the two groups (thigh 
and abdomen). Data are presented as the mean ± SE, with n = 6 (** p < 0.01). 
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cells obtained with the enzymatic method were able to reach confluence faster than cells obtained 
with the Rigenera® method, at high passages (i.e., 10), no statistically significant difference in cell 
number was observed between the Rigenera®-obtained cells and Collagenase digestion (Figure 3a,b, 
p-value < 0.05). This means that, at these passages, the growth rate was comparable. Figure 3c 
compares the replication rate (in terms of the number of cells at passage 2–6 and 10) of the thigh and 
abdomen. The difference is clear at the low cellular passage (3.02 × 105 cells for the thigh and 9.92 × 
104 cells of the abdomen at passage 2), while the difference between the thigh and abdomen was not 
statistically significant after a long period of culture and many passages (such as at p10) (p-value < 
0.05) (Figure 3c). Finally, the morphological analysis highlighted a slight difference between the thigh 
and abdomen: for example, the cells obtained from the abdomen were flatter and more widely spread 
(see Figure 3d). 
In order to compare the ability to form colonies of ASCs obtained from the thigh and abdomen, 
colony-forming unit-fibroblast (CFU-F) assays were performed. Figure 4 displays representative 
micrographs of CFU-F detected by Toluidine Blue staining after 15 days of Rigenera® treatment 
(Figure 4a, thigh, and b, abdomen) compared with enzymatic digestion (Figure 4d, thigh, and b, 
abdomen). The images show that both ASCs treated with Rigenera® and isolated from the thigh and 
abdomen were able to grow forming clusters, but larger colonies (formed by a higher number of cells) 
could be observed in samples obtained from the thigh compared to those from the abdomen (Figure 
4a,b). These differences are not evident in the samples treated with enzymatic digestion (Figure 4d,e). 
Figure 4. The colony-forming unit-fibroblast (CFU-F) assay of ASCs obtained by Rigenera® ((a)
thigh and (b) abdomen) and the enzymatic method ((d) thigh and (e) abdomen). CFU-F values were
determined at day 15 after plating using the Toluidine Blue staining method. ASCs extracted from the
thigh (a–d) formed larger colonies containing more cells than those extracted from the abdomen (b–e);
(c) CFU-F numbers at day 15 obtained by the Rigenera® device; CFU-F numbers showed significant
differences between the two groups (thigh and abdomen). (f) CFU-F numbers at day 15 obtained by
the enzymatic method; CFU-F numbers showed no significant differences between the two groups
(thigh and abdomen). Data are presented as the mean ± SE, with n = 6 (** p < 0.01).
In order to demonstrate the presence of ASCs in the Rigenera® product, an immunophenotypic
assay at p0 (immediately after the treatments) was performed. Figure 5 shows a scatter plot that
combines the signals obtained from the Forward Scatter (FSC) and Side Scatter (SSC). Based on the size,
shape, and internal structure of cells, it was possible to select the mesenchymal-like cells presented in
the scatter plot. The cytogram at p0 confirmed the much higher yield of stem cells for the enzymatic
method (12.7% of ASCs from the thigh and 4.36% of ASCs from the abdomen) (Figure 5a for the thigh,
and b for the abdomen) compared to Rigenera® (0.92% of ASCs from the thigh and 0.15% of ASCs
from the abdomen) (Figure 5c for the thigh, and d for the abdomen).
Subsequently, specific single antigens or a combination of two antigens were tested on the
previously selected cells. At p0, the ASCs isolated by the enzymatic method, including CD105, CD90,
CD73, CD44, and CD29 (Figure 6c–e), were expressed at a medium level, while the hematopoietic
marker CD45 (Figure 6a) was poorly expressed and the hematopoietic marker CD34 was highly
expressed (Figure 6).
An immunophenotyping analysis of the ASCs obtained from the Rigenera® method at p0 showed
a medium expression of mesenchymal stem cell markers (CD105, CD73, and CD29) (Figure 6c–e)
comparable with the results of the enzymatic method, confirming the presence of the ASC phenotype.
In contrast, a different expression of the hematopoietic marker CD34 (Figure 6b) was observed for
the two techniques. Indeed, this antigen was more highly expressed after collagenase digestion,
probably meaning that the Rigenera® method allowed the isolation of a purer cell population (see
Figure 7). Finally, we also identified a generally low (8%) and medium (20.8%) presence of multi-lineage
differentiating stress enduring cells (MUSE cells) for the enzymatic and Rigenera® method, respectively
(see Figures 6f and 7f). No differences in the marker expression level were found for the thigh and
abdomen (data not shown).
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Figure 5. Cytograms of enzymatic digestion (a, thigh; b, abdomen) and Rigenera® product (c, thigh; d,
abdomen) at passage 0. Mesenchymal-like cells was selected based on Forward Scatter (FSC) and Side
Scatter (SSC) information.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 8 of 17 
 
 
Figure 6. Flow cytometry after enzymatic digestion. Immunophenotyping analysis of ASCs at p0 from 
enzymatic digestion. Cell markers CD45 (a), CD34 (b), CD44/CD90 (c), CD73/CD105 (d), CD73/CD29 
(e), and SSEA3 (f). 
An immunophenotyping analysis of the ASCs obtained from the Rigenera® method at p0 
showed a medium expression of mesenchymal stem cell markers (CD105, CD73, and CD29) (Figure 
6c–e) comparable with the results of the enzymatic method, confirming the presence of the ASC 
phenotype. In contrast, a different expression of the hematopoietic marker CD34 (Figure 6b) was 
observed for the two techniques. Indeed, this antigen was more highly expressed after collagenase 
digestion, probably meaning that the Rigenera® method allowed the isolation of a purer cell 
population (see Figure 7). Finally, we also identified a generally low (8%) and medium (20.8%) 
presence of multi-lineage differentiating stress enduring cells (MUSE cells) for the enzymatic and 
Rigenera® method, respectively (see Figure 6f and Figure 7f). No differences in the marker expression 
level were found for the thigh and abdomen. 
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Figure 6. Flow cytometry after enzymatic digestion. I munophenotyping analysis of ASCs at p0 from
enzymatic digestion. Cell markers CD45 (a), CD34 (b), CD44/CD90 (c), CD73/CD105 (d), CD73/CD29
(e), and SSEA3 (f).
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Figure 7. Flow cytometry after Rigenera® treatment. Immunophenotyping analysis of ASCs at p0 from 
Rigenera® treatment. The presence of the ASC phenotype is confirmed. Cell markers CD45 (a), CD34 
(b), CD44/CD90 (c), CD73/CD105 (d), CD73/CD29 (e), and SSEA3 (f). 
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that the surface marker expression profiles of ASCs from the thigh and abdomen were comparable 
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In order to determine the multipotency of ASCs isolated from samples treated with Rigenera®, 
a differentiation assay for adipocyte, chondrocytes, and osteocytes was performed. In this 
experiment, we observed cellular differentiation macroscopically and the results were compared 
with those of the enzymatic method and non-induced cells (Figure 8). The adipogenic differentiation 
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Figure 7. Flow cytometry after Rigenera® treatment. Immunophenotyping analysis of ASCs at p0 from
Rigenera® treatment. The presence of the ASC phenotype is confirmed. Cell markers CD45 (a), CD34
(b), CD44/CD90 (c), 73/C 105 (d), CD73/CD2 ), and SSEA3 (f).
At a higher passage (p10), the antigen pattern was similar between cells obtained from the
Rigenera® and enzymatic ethod, resulting in a high expression of the mesenchymal stem cell surfac
marker and confirming phenoty e maintenance. The i munophenotypic analysis at p10 also showed
that the surface marker expression profiles of ASCs from the thigh and abdomen were comparable and
preserved over time.
In order to determine the multipotency of ASCs isolated from samples tr ated with Rigenera®,
a differentiation assay for adipocyte, chondrocytes, and osteocytes was performed. In this experiment,
we observed cellular differentiation macroscopically and the results were compared with those of
the enzymatic method and non-induced cells (Figure 8). The adipogenic differentiation of ASCs was
confirmed by Oil Red O staining after 14 days of induction. Compared to the non-induced cells
(Figure 8A (a–d)) the cells stained with Oil Red O solution showed the formation of lipid droplets
within the cytoplasm (Figure 8A (e–h)). Moreover, there were no notable differences between ASCs
isolated from the thigh and abdomen. The osteogenic potential was determined by Alizarin Red
Staining (Figure 8B (e–h)) to indicate the extracellular matrix calcification. Both samples (thigh and
abdomen) demonstrated positive staining in osteo-induced cells in contrast to the non-induced cells,
indicating the osteogenic differentiation of ASCs. Finally, ASCs were chondrogenically cultured for
3 weeks and stained with Alcian blue. Chondrogenesis was observed in all samples by the deposition
of sulfated proteoglycan-rich matrix (Figure 8C (e–h)). The differentiation potential between cells
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obtained with Rigenera® and enzymatic digestion was comparable. This result shows that ASCs
obtained with Rigenera® treatment are able to differentiate towards multilineage cell fates.
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Figure 8. Cell differentiation assay. Multilineage differentiation potential of the ASCs from the
thigh and abdomen after treatment with Rigenera® compared to enzymatic methods (EM). (A) Cells
were cultured with complete ASC medium (CRTL) (a,b,c, scale bar 100 µm, d scale bar 50 µm) and
adipogenic medium (AM) (e,f,g scale bar 100 µm, h scale bar 50 µm). In the adipogenic medium,
adipogenesis was indicated by the accumulation of neutral lipid vacuoles stained with Oil Red O, while
the nucleus was stained with hematoxylin. (B) Cells were cultured with complete ASC medium (CRTL)
(a,b,c scale bar 100 µm, d scale bar 50 µm) and osteogenic medium (OM) (e,f,g, h scale bar 100 µm).
In osteogenic medium, osteogenesis was indicated by Alizarin Red S staining of extracellular matrix
calcification, while the nucleus was stained with hematoxylin. (C) Cells were cultured with complete
ASC medium (CRTL) (a,c,d scale bar 50 µm, b scale bar 100 µm) and chondrogenic medium (CM) (e,f,g
scale bar 100 µm, h scale bar 50 µm). In chondrogenic medium, chondrogenesis was shown by the
deposition of sulfated proteoglycan-rich matrix stained with Alcian blue, while the nucleus was stained
with hematoxylin.
3. Discussion
Although the enzymatic method, which has been used for 40 years in the laboratory in order
to isolate cells, is the best method available, it is definitely not compatible with clinics, due to the
long-lasting procedure and legal restrictions [19,26–33]. Furthermore, it destroys the stem-cell niche,
which is the microenvironment which surrounds the stem cell, allowing interactions with neighboring
cells and promoting cell survival, proliferation, and differentiation [34,35]. Many efforts have been made
to establish a mechanical method with a yield comparable to the one of collagenase. Unfortunately,
so far, none of them have exhibited the same performance. In addition, in order to use it in clinics,
the method has to be fast, safe, standardized, and autologous. Rigenera® addresses all of these
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requirements. This technology allows the mechanical disaggregation of a small amount of adipose
tissue previously harvested from the same patient. Rigenera® technology provides selective filtration,
applying a filter of 80 µm, and the product is collected from the reservoir located at the bottom of the
Rigenera® device, making it a safe and closed device. The Rigenera® device can be used for various
problems, such as ulcers, alopecia, and post traumatic skin defects [36–41].
The product obtained with this technology consists of fragments of connective tissue (collagen
and elastic fibers) and isolated cells (Figure 1), among which mesenchymal-like cells, which are
considered the main agent responsible for the regenerative potential of the product [8,9]. In this study,
we conducted characterization in terms of the cell viability, cell morphology, and immunophenotyping
the mesenchymal-like cells obtained with the Rigenera® device.
We optimized the Rigenera® operating time, demonstrating that, to obtain a higher yield of cells,
the best choice is the mechanical disaggregation of adipose tissue for 60 s. Indeed, by processing the
adipose tissue by the ceramic blades contained in Rigenera® for 60 s, we obtained a higher number of
cells with better a replication capacity compared to the 30 and 45 s treatment. Our hypothesis is that a
short sample processing time is not enough to produce the proper mechanical disaggregation of fat
tissue, allowing only a partial extraction of cells contained within it. These limitations could affect the
clinical product’s efficiency.
We also proved that Rigenera® treatment does not affect the cell morphology, since the cell
appearance under the microscope was not altered and was also preserved over time (passages higher
than the ninth). In addition, when plated in a flask, the cells obtained by the Rigenera® device were able
to grow forming clusters, which is a typical feature of mesenchymal cells, named the colony-forming
capacity. Moreover, the differentiation potential of cells extracted with the Rigenera® device towards
adipogenic, osteogenic, and chondrogenic lineages was demonstrated. Unfortunately, the cell yield
and thus, the mean time of confluence, was lower compared to that of the enzymatic method, but
the replication rate was comparable at higher passages (from the tenth passage). The antibody
expression of the typical mesenchymal stem cell markers (CD105, CD90, CD73, CD44, and CD29)
and the hematopoietic markers (CD45 and CD34) was similar to that of the collagenase method and
preserved over time. Therefore, no alteration in the ASC phenotype was observed. Moreover, an
average expression of the MUSE-SSEA3 antigen was detected. MUSE cells are a subpopulation of
mesenchymal stem cells, double-positive for the mesenchymal marker CD105 and the pluripotency
marker stage-specific embryonic antigen-3 (SSEA-3), discovered by Kuroda in 2010 [12]. They are
known to be pluripotent, i.e., they are able to differentiate into cells belonging to the three germ layers
and able to endure stress, such as oxygen deprivation. For these reasons, they could be considered the
main agent responsible for regeneration and reparation [12,13]. The presence of MUSE cells, together
with multipotent cells, allows a significant advantage in tissue regeneration, as MUSE cells are present
in a variety of connective tissues. This provides safety and ethical advantages for clinical applications.
Finally, since surgeons harvest adipose tissues from various anatomical districts [42], we compared
the regenerative potential of the cells obtained from the thigh and abdomen. Although subcutaneous
regions are considered the most appropriate sites to harvest adipose tissue [42,43], we demonstrated
that the ASC yield (in terms of the number of cells extracted, replicative rate, and number of CFU)
from the thigh was higher than that from the abdomen, using the Rigenera® device. We found that
the progenitor cell frequencies (the ability to form colonies) were higher in ASCs extracted from the
thigh: these ASCs could produce more colonies containing larger numbers of cells compared to those
from the abdomen. Moreover, the immunophenotypic analysis confirmed that a much higher yield of
ASCs was obtained from thigh samples, although both the samples (thigh and abdomen) expressed a
phenotype profile specific for ASC markers. Moreover, a difference between cells obtained from the
thigh and abdomen was appreciable in terms of the cell morphology: abdomen cells were flatter and
more widely spread in the flask. This large and flat cell morphology is reflected in the lower replication
rate (number of cells at confluence) and in the greater amount of time required to reach confluence
compared to cells extracted from the thigh. These results demonstrated the characteristics of senescent
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cells [44]. These differences could be due to the fact that the thigh is often a virgin site of extraction and
the adipose tissue remains more uniform, with a collagen matrix being thinner than adipose tissue
obtained from the abdomen, resulting in a tissue that is easier to process with the Rigenera® device.
4. Materials and Methods
4.1. Adipose Tissue Sample Collection
The current non-enzymatic system (named Rigenera®, HBW, Turin, Italy) was designed to collect
and prepare human disaggregated biological tissue, such as dental pulp [25], dermis [26], scars [27],
cartilage [19], and adipose tissue, for re-injection. In this study, adipose tissue was harvested from nine
women subjected to liposuction, aged between 41 and 69 years. Consent was obtained prior to tissue
collection, according to the ethical guidelines set by the review board for human studies. The tissue
was subsequently processed with Rigenera® technology with 16 mL capsules, as described previously
by De Francesco and colleagues [18].
4.2. Cell Isolation and Culture
Each adipose tissue sample was divided into two portions. In the Rigenera® capsule, 4 mL
of lipoaspirate and 4 mL of the complete culture medium Dulbecco Minimum Essential Medium
(DMEM) (Merck KGaA, Darmstadt, Germany) containing 10% Fetal Bovine Serum (FBS), 1% of a
mix of penicillin/streptomycin 1:1 (GIBCO Life Technology, Monza, Italy), and 0.5% amphotericin B
(GIBCO Life Technology, Monza, Italy) were added. The Rigenera® device was operated for 30, 45, or
60 s. The collected cell pellet was withdrawn from the capsule by a syringe, filtered through a 70-µm
nylon mesh, and centrifuged at 3000 rpm for 7 min. The supernatant was discarded, and the cell
pellet was resuspended in 6 mL of complete medium, plated in a 25 cm2 flask (BD FalconTM, Becton
Dickinson, Milano, Italy), and incubated at 37 ◦C and 5% CO2. The second portion of lipoaspirate was
digested with collagenase following the collagenase protocol, as reported in [23]. Briefly, 4 mL was
digested with 1 mg/mL type I collagenase (GIBCO life technology, Monza, Italy) in Hank’s Balanced
Salt Solution (HBSS) and 2% bovine serum albumin (BSA) at 37 ◦C for 45 min. The enzymatic action
was neutralized by adding complete medium. Then, the sample was centrifuged at 3000 rpm for 7 min,
the supernatant was discarded, and the cell pellet was incubated with 3 mL of 160 mM NH4Cl at room
temperature for 10 min to lyse the erythrocytes. After centrifugation, the cells were resuspended in
6 mL of complete medium, filtered through a 70-µm nylon mesh, plated in a 25 cm2 flask with complete
culture medium, and incubated at 37 ◦C and 5% CO2. The medium was first changed after 72 h and,
successively, every 48 h. At confluence, cells were detached by incubating them with trypsin-EDTA 1%
(GIBCO Life Technology, Monza, Italy) at 37 ◦C for 5 min and re-plated in a 75 cm2 flask.
4.3. Morphological Analysis: Scanning and Transmission Electron Microscopy
For transmission electron microscopy, the pellets of the product obtained after the treatment with
Rigenera 60” were fixed with glutaraldehyde 2% in Sorensen buffer pH 7.4 for 2 h, post-fixed in 1%
osmium tetroxide in aqueous solution for 2 h, and dehydrated in graded concentrations of acetone.
At the end of the dehydrating process, samples were positioned in a multi-well grid for electron
microscopy and observed using an EM10 electron microscope (Zeiss, Oberkochen, Germany).
For scanning electron microscopy analysis, the pellets of the product obtained after the treatment
with Rigenera 60” were fixed to 2% glutaraldehyde in a phosphate buffer for 2–4 h, post-fixed in 1%
osmium tetroxide in the same buffer for 1 h, and dehydrated in graduated acetone concentrations.
The samples were then treated with a critical-point dryer (CPD 030, Balzers Vaduz, Liechtenstein),
mounted on metal samples, and coated with gold (MED 010 Balzers). SEM imaging was performed
with XL30 ESEM (FEI-Philips Eindhoven, The Netherlands).
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4.4. Morphological Analysis and Cell Viability Test
Morphological analysis of the cells obtained with the three different Rigenera® operating timings
and the enzymatic method, and from the two different harvesting sites, was performed by visualizing
them under a light microscope (Optika Microscopes, Ponteranica, Italy). The cell viability and growth
rate were evaluated by the cell viability test with the trypan blue exclusion method.
4.5. Cell Colony-Forming Unit Assay
A colony-forming unit-fibroblast (CFU-F) assay was performed for cells treated with Rigenera®
and enzymatic digestion. Briefly, cells isolated from the thigh and abdomen and treated with the
Rigenera® device were plated in 6-well culture plates at a density of 3000 cells/cm2 and cultured in the
complete media. On the 15th day after plating, the total number of cell colonies (CFU-F, a cluster of at
least 50 adhered and fibroblast-like cells) was stained with Toluidine Blue (Sigma) and counted.
4.6. Immunophenotyping
After isolation, cells were counted and 2 × 105 cells were placed in a tube for cytofluorimetric
analysis. The pellet was washed with 1 mL of 1% FBS in PBS and then labeled with fluorescent-dye
conjugated antibodies in a final volume of 100 µL and incubated for 30 min in ice. The examined
antibodies were APC-conjugated CD90 (dilution 1:5), PerCP-Cyt5.5-conjugated CD105 (dilution 1:20),
BV421-conjugated CD73 (dilution 1:20), BV785-conjugated CD44 (dilution 1:20), PE-conjugated CD34
(dilution1:5), FITC-conjugated CD29 (dilution 1:20), and BV650-conjugated CD45 (dilution 1:20). All
of the antibodies were purchased from BD Biosciences, (Becton Dickinson Italy S.p.A., Milan, Italy).
Alexa Fluor-488-conjugated SEEA3 (dilution 1:20) was purchased from Aurogene (Aurogene S.R.L,
Rome, Italy). After the incubation, the pellet was rinsed, resuspended in 300 µL of 1% FBS in PBS, and
transferred in flow cytometry tubes. The immunophenotyping was performed through an FACS canto
II (BD, Becton Dickinson, Italy).
4.7. Cell Differentiation Assay
The multilinear differentiation potential was evaluated by testing the ability of the product
obtained after treatment with Rigenera (60 s) and the enzymatic method to differentiate into
adipocytes, chondrocytes, and osteocytes. Briefly, adipocyte differentiation was achieved after
16 days culture of MSCs with adipogenic medium, containing 10−6 M dexamethasone, 10 µg/mL
insulin, and 100 µg/mL 3-isobutyl-1-methylxantine (Sigma). Chondrocyte differentiation was achieved
after 14 days culture with the StemPro osteogenesis differentiation kit (GIBCO Life Technology,
Italy). Osteoblast differentiation was achieved after 21 days culture with the StemPro osteogenesis
differentiation kit (GIBCO Life Technology, Italy). Oil Red O, Alcian blue, and Alizarin Red Stain were
employed to identify adipocytes, chondrocytes, and osteocytes, respectively.
4.7.1. Adipogenic Differentiation
A total of 7000 cells were seeded on the slides in the 6-well plate. After 24 h, the media was
changed to adipogenic medium. To confirm adipogenic differentiation, after 16 days, the cells were
fixed with 4% paraformaldehyde (PFA) for 30 min, washed, and stained with a solution of Oil Red
O (Bioptica) for 20 min and hematoxylin (Bioptica) for 2 min. They were then washed with distilled
water. Images were obtained using optical microscopy.
4.7.2. Chondrogenic Differentiation
1 × 106 cells were seeded on the slides in the 24-well plate, and after 2 h, the media was changed
to chondrogenic medium. To confirm chondrogenic differentiation, after 14 days, cells were fixed with
4% PFA for 30 min, and Alcian Blue 8GX (Sigma-Aldrich) was used to stain the extracellular matrix
mucopolysaccharides and hematoxylin (Bioptica) for 2 min. The staining solution was prepared by
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dissolving 1% Alcian Blue 8GX in 0.1 N HCl. This solution was filtered and added to each culture
well for 30 min, and the cells were then washed with distilled water. Images were obtained using
optical microscopy.
4.7.3. Osteogenic Differentiation
In total, 5000 cells were seeded on the slides in the 12-well plate. After 2 h, the media was changed
to osteogenic medium. To confirm osteogenic differentiation, after 21 days, cells were fixed with 4%
PFA for 30 min and incubated in 0.2% Alizarin Red S (Sigma-Aldrich) for 5 min and hematoxylin
(Bioptica) for 2 min. Then, they were washed with PBS (Gibco), and images were obtained using
optical microscopy.
The cells of the control group were cultured with the ASC complete medium (Dulbecco’s Modified
Eagle Medium (DMEM), 10% FBS, and 1% penicillin/streptomycin) and the cells were stained with
hematoxylin to highlight the nucleus.
4.8. Statistical Analysis
Data were expressed as the mean ± standard deviation. Unpaired sample student’s t-tests
were performed and differences between two groups were considered statistically significant, when
p-value < 0.05.
4.9. Ethics Statement
The study respects all ethical requirements in its objectives and methodologies. We have strictly
complied with widely recognized international codes of practice, such as the Nuremberg code, the
Helsinki agreement, the conventions of the Council of Europe on human rights and biomedicine,
with particular attention to EU legislation: 2001/83/EC, 86/609/EEC, and FP7 Decision nr 1982/2006EC.
Human biological samples were required because we needed to test human cells, which have unique
biological characteristics, distinct from those of animals. The overall intention of the project was to
reduce the number of animal experiments. Only adult patients who were able to give consent were
included. All the patients, which were the subjects of our study, gave their consent with regards
to scientific treatment and publication of their clinic situation and images. We obtained written
informed consent from all patients. This study was approved by our Internal Ethical Committee
(CERM committee – 2019/27/Rig1), without any registration in public registry, because this study is not
a clinical trial.
5. Conclusions
Although the enzymatic method, which has been used for 40 years in the laboratory in order
to isolate cells, is the best available method, it is definitely not compatible with clinics, due to the
long-lasting procedure and legal restrictions. Many efforts have been made to establish a mechanical
method with a yield comparable to that of collagenase. Unfortunately, so far, none of them have
displayed the same performance. In addition, in order to use it in vivo, a closed device is needed,
and the method has to be fast, safe, standardized, and autologous. Rigenera® addresses all of these
requirements. In this study, we characterized in vitro the Rigenera® product, focusing on two sites of
adipose tissue harvesting. At first, we optimized the Rigenera® operating time, demonstrating that
60 s of treatments allows a higher cellular yield to be obtained, in terms of the cell number and growth
rate. This result optimizes the mechanical disaggregation and it can increase the clinical efficiency of
the final product. Comparing the thigh and abdomen, our results showed that the thigh provides a
higher number of mesenchymal-like cells, with a faster replication rate and a higher ability to form
colonies. Finally, the immunophenotypic analysis confirmed that a much higher yield of ASCs was
obtained from thigh samples. We can conclude that, by collecting adipose tissue from the thigh and
treating it with the Rigenera® device for 60 s, it is possible to obtain the most efficient product. This
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should lead surgeons to prefer the thigh as a harvesting site, especially for surgeries that require a
small amount of injectable volume.
Our future work will involve a better characterization, conducted through a biomolecular analysis
of the final product of Rigenera®, such as the expression level of genes involved in stemness; adipogenic,
osteogenic, and chondrogenic differentiation or angiogenesis; inflammation; and cell aging.
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